{"id":"https://openalex.org/W2154169171","doi":"https://doi.org/10.1200/jco.2004.03.050","title":"Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients","display_name":"Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients","publication_year":2004,"publication_date":"2004-02-27","ids":{"openalex":"https://openalex.org/W2154169171","doi":"https://doi.org/10.1200/jco.2004.03.050","mag":"2154169171","pmid":"https://pubmed.ncbi.nlm.nih.gov/14990650"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.03.050","doi":"https://doi.org/10.1200/jco.2004.03.050","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2004.03.050","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2004.03.050?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2004.03.050?role=tab","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100642759","display_name":"Bin Peng","orcid":"https://orcid.org/0000-0001-5211-1544","observed_orcids":["https://orcid.org/0000-0001-5211-1544"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bin Peng","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011431249","display_name":"Michael Hayes","orcid":"https://orcid.org/0000-0002-9215-1484","observed_orcids":["https://orcid.org/0000-0002-9215-1484"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Hayes","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061755998","display_name":"Debra J. Resta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debra Resta","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029859827","display_name":"Amy Racine-Poon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Racine-Poon","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125591963","display_name":"Brian J. Druker","orcid":"https://orcid.org/0000-0001-8331-8206","observed_orcids":["https://orcid.org/0000-0001-8331-8206"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian J. Druker","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011529063","display_name":"Moshe Talpaz","orcid":"https://orcid.org/0000-0003-3361-3981","observed_orcids":["https://orcid.org/0000-0003-3361-3981"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moshe Talpaz","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034963668","display_name":"Charles L. Sawyers","orcid":"https://orcid.org/0000-0003-4955-6475","observed_orcids":["https://orcid.org/0000-0003-4955-6475"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles L. Sawyers","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055596167","display_name":"Marianne Rosamilia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marianne Rosamilia","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014972879","display_name":"J. Ford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Ford","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112508130","display_name":"Peter M. Lloyd","orcid":"https://orcid.org/0009-0007-2337-7459","observed_orcids":["https://orcid.org/0009-0007-2337-7459"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Lloyd","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022108188","display_name":"Renaud Capdeville","orcid":"https://orcid.org/0000-0001-7611-0765","observed_orcids":["https://orcid.org/0000-0001-7611-0765"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Renaud Capdeville","raw_affiliation_strings":["From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Pharma AG, Basel, Switzerland; Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR; The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I161318765","https://openalex.org/I165690674"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":20.3998,"has_fulltext":true,"cited_by_count":472,"citation_normalized_percentile":{"value":0.99737961,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"22","issue":"5","first_page":"935","last_page":"942"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/imatinib-mesylate","display_name":"imatinib mesylate","score":0.9509999752044678},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9340000152587891},{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-leukemia","display_name":"Philadelphia chromosome-positive leukemia","score":0.843999981880188},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9539999961853027},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9940000176429749},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6980000138282776},{"id":"https://openalex.org/keywords/drug-accumulation","display_name":"drug accumulation","score":0.8109999895095825},{"id":"https://openalex.org/keywords/trough-concentration","display_name":"trough concentration","score":0.7329999804496765},{"id":"https://openalex.org/keywords/white-blood-cell-reduction","display_name":"white blood cell reduction","score":0.6970000267028809},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5699999928474426}],"concepts":[{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8587682247161865},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8499524593353271},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.792741060256958},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7884571552276611},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7234331369400024},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.6324666142463684},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6118805408477783},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5872659683227539},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.4732521176338196},{"id":"https://openalex.org/C79410662","wikidata":"https://www.wikidata.org/wiki/Q1251001","display_name":"Dose\u2013response relationship","level":2,"score":0.45940226316452026},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33197784423828125}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.03.050","doi":"https://doi.org/10.1200/jco.2004.03.050","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2004.03.050","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2004.03.050?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:14990650","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14990650","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1200/jco.2004.03.050","doi":"https://doi.org/10.1200/jco.2004.03.050","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2004.03.050","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2004.03.050?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.800000011920929,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2154169171.pdf","grobid_xml":"https://content.openalex.org/works/W2154169171.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W43422572","https://openalex.org/W120676909","https://openalex.org/W1490860457","https://openalex.org/W1969787124","https://openalex.org/W1991417422","https://openalex.org/W2006917576","https://openalex.org/W2015616444","https://openalex.org/W2016086822","https://openalex.org/W2060317640","https://openalex.org/W2074740152","https://openalex.org/W2091897921","https://openalex.org/W2107015590","https://openalex.org/W2107582371","https://openalex.org/W2112163451","https://openalex.org/W2133347849","https://openalex.org/W2142969636","https://openalex.org/W2218367024","https://openalex.org/W2312804644","https://openalex.org/W2314938037","https://openalex.org/W2329648702","https://openalex.org/W3174623534"],"related_works":["https://openalex.org/W2002247001","https://openalex.org/W2123135404","https://openalex.org/W2070391470","https://openalex.org/W2161653304","https://openalex.org/W2149815987","https://openalex.org/W2091813747","https://openalex.org/W2121209161","https://openalex.org/W1541103017","https://openalex.org/W1970516173","https://openalex.org/W2115473091"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"evaluate":[2],"the":[3,13,16,23,65,75,99,119,162,180,186,200,207,231],"basic":[4],"pharmacokinetic":[5],"(PK)":[6],"characteristics":[7],"of":[8,22,33,61,80,122,153,156,170,175,210,230,246],"imatinib":[9,34,53,157],"mesylate":[10],"and":[11,18,30,105,215,237],"assess":[12],"relationship":[14,100,232],"between":[15,101,233],"PK":[17,29,59,238],"pharmacodynamic":[19],"(PD)":[20],"properties":[21,32],"drug.":[24],"PATIENTS":[25],"AND":[26],"METHODS:":[27],"The":[28],"PD":[31,71,234,255],"were":[35,69],"investigated":[36],"during":[37],"a":[38,129,218,244],"phase":[39],"I":[40],"trial":[41],"that":[42,179,243],"included":[43],"64":[44],"adult":[45],"patients":[46,190],"with":[47,82,191],"Philadelphia":[48],"chromosome-positive":[49],"leukemias.":[50],"Patients":[51],"received":[52],"orally":[54],"once":[55],"or":[56,249],"twice":[57],"daily.":[58],"parameters":[60,239],"imatinib,":[62,83],"derived":[63],"from":[64],"plasma":[66,140],"concentration-time":[67,201],"curves,":[68],"determined.":[70],"response,":[72],"defined":[73],"as":[74],"WBC":[76,104],"after":[77,115,135,151,226],"1":[78,147],"month":[79],"treatment":[81],"was":[84,95,112,128,143],"used":[85,96],"to":[86,97,124,131,167,212,220],"develop":[87],"an":[88],"efficacy":[89],"model.":[90],"A":[91],"maximum":[92],"inhibition-effect":[93],"model":[94],"describe":[98],"reduction":[102],"in":[103],"drug":[106,133,222],"exposure":[107,111,197],"parameters.":[108],"RESULTS:":[109],"Imatinib":[110],"dose":[113,120,188,204,208,245],"proportional":[114,205],"oral":[116],"administration":[117,152],"for":[118,189,206,253],"range":[121,209],"25":[123,211],"1,000":[125,213],"mg.":[126],"There":[127],"1.5-":[130,219],"three-fold":[132,221],"accumulation":[134,223],"repeated":[136],"once-daily":[137,227],"dosing.":[138,228],"Mean":[139],"trough":[141],"concentration":[142,165],"0.57":[144],"microg/mL":[145],"(approximately":[146],"micromol/L)":[148],"24":[149],"hours":[150],"350":[154],"mg":[155,248],"at":[158,224,240],"steady-state,":[159],"which":[160],"exceeds":[161],"50%":[163],"inhibitory":[164],"required":[166,252],"inhibit":[168],"proliferation":[169],"Bcr-Abl-positive":[171],"leukemic":[172],"cells.":[173],"Analysis":[174,229],"PK/PD":[176],"relationships":[177],"indicates":[178,242],"initial":[181],"hematologic":[182],"response":[183],"depends":[184],"on":[185],"administered":[187],"chronic":[192],"myeloid":[193],"leukemia.":[194],"CONCLUSION:":[195],"Drug":[196],"(area":[198],"under":[199],"curve)":[202],"is":[203,217,251],"mg,":[214],"there":[216],"steady-state":[225,241],"(WBC":[235],"reduction)":[236],"400":[247],"greater":[250],"maximal":[254],"effect.":[256]},"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":12},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":14},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":19},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":16},{"year":2014,"cited_by_count":24},{"year":2013,"cited_by_count":33},{"year":2012,"cited_by_count":29}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2025-10-10T00:00:00"}